Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Optimal induction therapy in high risk multiple myeloma

Saad Zafar Usmani, MD, reports on the primary analysis of the phase II  SWOG-1211 trial, in which bortezomib, lenalidomide, dexamthasone are tested with or without elotuzumab in newly diagnosed, high-risk multiple myoloma.

  • Sponsors

    This program is editorially independent and is financially supported by:

Related items